STEVEN BLOOM

Photoredox catalysis has emerged as an attractive tool for medicinal chemistry, streamlining both targeted drug synthesis and late-stage molecular editing. Research in the Bloom group seeks to harness this multifarious platform to address key challenges at the interface of synthetic chemistry and biotechnology.

Specifically, our group is interested in the use of photoredox catalysis for the synthesis of peptide and protein-based therapeutics. Among our current interests are the development of chemical methods for the controlled synthesis of non-classical peptides, peptibodies, fusion proteins, bispecific antibody constructs, and peptide/protein-based drug conjugates for use in targeted therapy.